Buy MONOVISC®
Showing the single result
-


MONOVISC®
$ 369.00 Add To Cart-+MONOVISC® is a single-injection hyaluronic acid viscosupplement developed by Anika Therapeutics, formulated as 88 mg of ultra-pure cross-linked HA in a 4 mL intra-articular injection for osteoarthritis knee pain relief. FDA-cleared and supported by a double-blind, randomized, placebo-controlled clinical trial, MONOVISC® offers licensed practitioners a single injection treatment that reduces the patient burden of multi-injection regimens. Direct Doctors Supply has been a trusted wholesale supplier to licensed medical professionals since 2014, offering reliable stock, competitive pricing, and dedicated support. Browse the MONOVISC® catalog below to order MONOVISC® for your clinic today.
About MONOVISC® — One Injection, Long-Term Osteoarthritis Relief
MONOVISC® is indicated for the treatment of pain associated with knee osteoarthritis in patients who have not achieved adequate relief from conservative non-pharmacologic therapies and simple analgesics [3]. FDA-cleared as a medical device, it is manufactured by Anika Therapeutics, a US-based medical technology company focused on joint preservation and regenerative medicine [3][5].
The product’s defining feature is its single-injection treatment regimen. Each treatment cycle consists of one 4 mL intra-articular injection containing 88 mg of ultra-pure, cross-linked sodium hyaluronate at a concentration of 22 mg/mL [3]. This distinguishes MONOVISC® from viscosupplements that require multiple injections over several weeks, reducing the treatment burden for both patients and practitioners. Repeat treatment cycles may be considered based on symptom recurrence and clinical assessment [3].
Who Is MONOVISC® For? — Patient Indications and Treatment Areas
MONOVISC® is indicated for adults with symptomatic osteoarthritis in the knee joint who have not achieved adequate pain control through conservative therapies such as physical therapy, weight management, or oral analgesics [3]. The patient profile best suited to MONOVISC® includes osteoarthritis sufferers seeking long-term relief from osteoarthritis with minimal clinic visits, particularly those for whom multi-injection courses present practical or compliance challenges.
The FDA-cleared indication for MONOVISC® is the knee joint [3]. Published clinical discussions reference intra-articular HA use in other joints, including the knee, hip, shoulder, and ankle [2]. Any application beyond the knee falls outside the FDA-cleared label and constitutes off-label use, which should be approached in accordance with applicable clinical guidelines and institutional policies.
How MONOVISC® Works — Ultra-Pure HA Viscosupplementation
In healthy joints, hyaluronic acid maintains the viscoelastic characteristics of synovial fluid, providing lubrication and shock absorption during movement. Osteoarthritis is associated with a decline in both the concentration and molecular weight of endogenous HA, resulting in reduced joint lubrication and increased mechanical stress on cartilage [1][3].
A single intra-articular injection of MONOVISC® supplements the hyaluronic acid naturally present in the knee, helping restore the lubricating properties of the synovial environment and deliver pain relief in the knee affected by osteoarthritis [1][3]. The formulation contains 22 mg/mL of ultra-pure hyaluronic acid, cross-linked, with high molecular weight and low protein content, produced through a non-avian fermentation process [3]. In a landmark multicenter, double-blind, randomized, placebo-controlled trial [1], a single MONOVISC® injection produced statistically significant knee pain relief with MONOVISC®, and the durable relief with MONOVISC® was reflected in responder rates and improvement from baseline favoring the active treatment group [1].
MONOVISC® is not a steroid injection. It contains no corticosteroids and functions as a hyaluronic acid medical device rather than a pharmaceutical therapy [3]. Its mechanism supplements synovial fluid rather than modulating inflammation through drug-based activity, which is why the lubricating properties of MONOVISC® come from HA replacement rather than anti-inflammatory drug action.
MONOVISC® Product Spotlight
MONOVISC® 88 mg / 4 mL has a single formulation and a single format, designed for a specific clinical purpose:
- Hyaluronic acid concentration: 22 mg/mL
- Total HA per dose: 88 mg in 4 mL
- HA type: cross-linked, ultra-pure, non-avian fermentation-derived
- Administration: single intra-articular injection per treatment cycle
- Regulatory status: FDA-cleared for knee osteoarthritis pain management
- Manufacturer: Anika Therapeutics, Inc.
MONOVISC® dosage is fixed at 88 mg of hyaluronic acid in a single 4 mL intra-articular injection, with no split-dose or multi-vial configurations [3]. Because it is a viscous HA solution delivered in one syringe, some clinic teams informally describe MONOVISC® gel injection, though the product is a cross-linked sodium hyaluronate device. Practitioners should refer to the current IFU for full dosing, handling, and storage specifications.
MONOVISC® injection price is quoted per account rather than from a single list figure, since wholesale pricing moves with order volume and terms; the Direct Doctors Supply support team can confirm current pricing. Practitioners who look for MONOVISC® injection reviews before adopting a new viscosupplement will find the peer-reviewed RCT evidence a firmer basis for evaluation than anecdotal MONOVISC® reviews [1].
About the Manufacturer — Anika Therapeutics
Anika Therapeutics is a US-based global medtech company with deep expertise in hyaluronic acid science and a focus on joint preservation and regenerative medicine [3][5]. Its orthopedic portfolio includes MONOVISC®, ORTHOVISC®, and CINGAL®, three HA-based viscosupplementation products covering different treatment formats and patient needs [3].
MONOVISC® and ORTHOVISC® share the same Anika Therapeutics ultra-pure HA manufacturing platform, giving practitioners confidence in consistency and purity across both products [3]. Anika’s track record of FDA-cleared products and clinical validation supports its standing as a recognized name in evidence-based viscosupplementation.
Why Practitioners Choose MONOVISC®
Among the single-injection viscosupplements on the market, MONOVISC® occupies a well-defined clinical and commercial position. Two differentiators consistently drive practitioner preference.
1. Single-Injection Convenience
MONOVISC®’s one-injection-per-cycle format reduces patient burden compared to three-injection alternatives such as EUFLEXXA® or multi-injection courses such as SUPARTZ® [2][3]. For osteoarthritis sufferers with mobility limitations, transport challenges, or demanding schedules, fewer clinic visits directly support better treatment adherence. For practitioners, a single-visit format simplifies scheduling and reduces the administrative complexity of managing multi-week injection series, a practical advantage in high-volume orthopedic and sports medicine settings.
2. Anika Therapeutics Ultra-Pure HA and Clinical Pedigree
A pivotal randomized controlled trial demonstrated statistically significant pain reduction with a single MONOVISC® injection compared to placebo, with improvement from baseline observed in the active treatment group [1]. MONOVISC® is also recognized under Medicare viscosupplementation coverage criteria, supporting reimbursement for eligible patients in the US market [4].
Administration and Aftercare
MONOVISC® is administered as a single intra-articular injection into the knee joint. Before injecting, any substantial joint effusion should be aspirated, as dilution of the HA solution may affect outcomes [3]. The injection should be performed under aseptic conditions by a trained practitioner; refer to the current IFU for complete technique guidance [3].
Onset of relief varies between individuals. The Petterson and Plancher RCT documented improvement from baseline building progressively following injection [1]. MONOVISC® is not an immediate-relief agent comparable to corticosteroids.
MONOVISC® injection aftercare requires patients to avoid strenuous or prolonged weight-bearing activity for approximately 48 hours following injection [3]. Mild transient discomfort or swelling at the injection site is normal and typically resolves within a day or two. MONOVISC® injection recovery time is short for most patients, who resume normal daily activities within one to two days, though more physically active patients should observe the 48-hour restriction [3]. Practitioners should advise patients to contact the clinic if they experience severe or prolonged swelling, significant warmth, or systemic symptoms.
Distribution and Market Availability
MONOVISC® is an FDA-cleared medical device available in the United States and through authorized international distributors. Anika Therapeutics supplies MONOVISC® injections through its established commercial channels, and availability may vary by country depending on local regulatory clearance and distributor agreements. Any distributor should confirm documented handling and reliable shipping timelines before delivery is accepted.
Direct Doctors Supply has served as a trusted wholesale supplier of orthopedic injectables and aesthetic medical devices since 2014. Licensed practitioners can buy MONOVISC® online through the Direct Doctors Supply catalog with confidence in stock availability, competitive pricing, and reliable delivery. The Direct Doctors Supply support team is available for bulk order inquiries, product questions, and order tracking.
Practitioners sourcing across product categories can buy orthopedic injections from the same professional wholesale platform, which also covers viscosupplements and other joint treatments. Multi-specialty practices can also buy dermal fillers through Direct Doctors Supply alongside their orthopedic orders.
Regulatory Status and Medicare Coverage
MONOVISC® is an FDA-cleared medical device indicated for the management of pain associated with knee osteoarthritis in patients with an inadequate response to conservative non-pharmacologic therapy and simple analgesics [3]. It is regulated as a medical device, not a pharmaceutical drug [3].
Medicare coverage may be available under Medicare Part B when applicable viscosupplementation criteria are met [4]. Practitioners should verify current CMS policy and confirm that individual patients meet the program’s clinical requirements before treatment, as coverage terms and eligibility criteria may change over time [4]. Private insurance coverage is also commonly available, though plan-specific verification is recommended.
Buy MONOVISC® Wholesale Through Direct Doctors Supply
Clinics that buy MONOVISC® wholesale benefit from a supplier that pairs verified product with responsive procurement support. To order MONOVISC® online in clinic quantities, or to discuss volume terms, teams can work directly with the Direct Doctors Supply support team before an order is placed. Aesthetic-focused practices that also stock HA products can buy HA dermal fillers within the same catalog, keeping orthopedic and cosmetic ordering on one platform. Availability is limited to qualified professionals, and shipping runs through documented channels with delivery timelines suited to clinical scheduling.
MONOVISC® vs Competing Viscosupplements
MONOVISC® vs ORTHOVISC®
Practices that prefer a course-based approach from the same manufacturer often buy ORTHOVISC® for patients who benefit from the extra monitoring points a multi-visit course provides. Both MONOVISC® and ORTHOVISC® come from Anika Therapeutics and share the same ultra-pure, fermentation-derived HA platform, so the defining distinction is the regimen: MONOVISC® is one intra-articular injection per cycle, while ORTHOVISC® runs three to four weekly injections [2][3].
MONOVISC® vs SYNVISC®
SYNVISC® and its single-injection formulation, SYNVISC-ONE®, are composed of hylan G-F 20, a cross-linked derivative from avian (rooster comb) tissue [2]. Clinicians whose patient mix suits an avian cross-linked formulation buy SYNVISC® on that clinical basis, while MONOVISC® uses non-avian, fermentation-derived ultra-pure HA that eliminates avian-material concerns [3]. Both offer single-injection convenience, so HA source, purity, and allergy history are the real deciding factors.
MONOVISC® vs EUFLEXXA®
EUFLEXXA® shares MONOVISC®’s non-avian fermentation-derived HA source but requires three weekly injections rather than a single visit [2][3]. Practitioners who prefer the clinical monitoring provided by a multi-injection course throughout the treatment period can buy EUFLEXXA® through Direct Doctors Supply.
MONOVISC® vs HYALGAN®
For a patient mix where an avian multi-injection product is the better clinical fit, practitioners buy HYALGAN® and reserve MONOVISC® for single-visit candidates. HYALGAN® is an avian-derived, lower-molecular-weight HA viscosupplement given over three to five weekly injections, so compared with MONOVISC® it means more patient visits and a different HA source [2].
MONOVISC® vs SUPARTZ®
SUPARTZ® is an avian-derived HA product given over a three- to five-injection weekly course [2]. Procurement teams sometimes buy SUPARTZ® alongside MONOVISC® to evaluate both on their own patients, since the two sit at opposite ends of the injection-count spectrum. Its avian origin and longer schedule contrast directly with MONOVISC®’s non-avian source and single-injection format [3].
MONOVISC® vs DUROLANE®
DUROLANE® is the most direct single-injection peer to MONOVISC®: both offer a single intra-articular injection per cycle and use non-avian HA sourcing [2]. Differentiating factors include molecular weight profile, concentration, clinical trial evidence base, and regional availability. Practitioners should evaluate both options based on their patient population and the available clinical evidence.
MONOVISC® Safety Profile
MONOVISC® has a well-characterized safety profile, consistent with that of intra-articular HA injections in general. The most commonly reported adverse events are localized to the injection site and include transient pain, swelling, warmth, and mild erythema [1][3]. These reactions are typically self-limiting, and injection-site discomfort from a MONOVISC® knee injection usually resolves within a few days.
Rare but more significant adverse events include acute local joint reactions characterized by marked swelling, warmth, and pain in the injected joint. These are uncommon and typically resolve with conservative management; practitioners should monitor for them and exclude infectious etiology if a severe joint reaction occurs [3]. The side effects of MONOVISC® injection are consistent with those documented for intra-articular HA viscosupplements as a class [1][2].
Contraindications include known hypersensitivity to hyaluronic acid or any component of the formulation, active joint infection, and skin disease or infection at the proposed injection site [3]. MONOVISC® should not be injected into a joint with active effusion without prior aspiration. Practitioners should refer to the current IFU for the complete contraindications, precautions, and storage requirements before use [3].
FAQs
What is MONOVISC®?
MONOVISC® is an FDA-cleared, single-injection hyaluronic acid viscosupplement manufactured by Anika Therapeutics. It contains 88 mg of ultra-pure, cross-linked, non-avian HA in a 4 mL pre-filled syringe and is indicated for the management of knee osteoarthritis pain in patients with an inadequate response to conservative therapy and simple analgesics [3].
Is MONOVISC® a one-time injection?
One injection per treatment cycle, not a single lifetime treatment. Most patients receive repeated cycles as knee OA symptoms recur, with retreatment intervals guided by clinical response [3]. The single-injection format distinguishes MONOVISC® from multi-injection courses such as ORTHOVISC® (three to four injections) or SUPARTZ® (three to five injections) [2][3].
How does MONOVISC® work?
The MONOVISC® knee injection restores the viscoelastic properties of synovial fluid in the osteoarthritic knee by supplementing the hyaluronic acid naturally present in healthy joints. This improves joint lubrication and cushioning, reducing the mechanical friction and discomfort associated with osteoarthritis [1][3]. Its mechanism is mechanical rather than pharmacological.
How is MONOVISC® administered?
MONOVISC® is administered as a single intra-articular injection into the knee joint under aseptic conditions, with any substantial joint effusion aspirated beforehand. The full procedure should follow the current IFU [3].
Is MONOVISC® a steroid?
No. MONOVISC® is a hyaluronic acid medical device with no steroid component, regulated as a medical device rather than a pharmaceutical drug [3]. Patients who ask are often comparing it to corticosteroid injections, which work through a different mechanism entirely.
How long does it take for MONOVISC® injection to work?
Onset varies between individuals. A pivotal randomized controlled trial documented improvement from baseline within the follow-up period, with the treatment effect building progressively after injection [1]. MONOVISC® is not comparable in onset speed to a corticosteroid injection; practitioners should set appropriate patient expectations before treatment.
What are the side effects of MONOVISC® injection?
The most commonly reported MONOVISC® injection side effects are localized reactions at the injection site, pain, swelling, and warmth, generally mild and transient and resolving within a few days. Serious adverse events such as acute joint reactions are uncommon [1][3].
Does Medicare cover MONOVISC®?
Coverage may be available under Medicare Part B when applicable viscosupplementation criteria for knee osteoarthritis are met [4]. Practitioners should verify current CMS policy and confirm individual patient eligibility before treatment, as coverage terms and requirements may change.
MONOVISC® vs ORTHOVISC® — what is the key difference?
Both are ultra-pure HA viscosupplements manufactured by Anika Therapeutics using the same underlying HA technology [3]. The difference is treatment format: MONOVISC® requires a single intra-articular injection per cycle, while ORTHOVISC® is a course of three to four weekly injections [2][3]. The choice comes down to patient compliance preference and clinic scheduling, not HA quality, which is equivalent across both products.
Looking to buy MONOVISC® products?
Direct Doctors Supply stocks MONOVISC® 88 mg/4 mL for licensed practitioners and clinic procurement teams through a professional wholesale catalog. Individual and bulk ordering options are available, with dedicated support staff, competitive pricing, and reliable delivery to hospitals, clinics, and healthcare facilities. To purchase MONOVISC® online or explore volume pricing, browse the catalog above or contact the Direct Doctors Supply support team directly.
Citations and Resources about MONOVISC®
[1] Petterson SC, Plancher KD. Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial. Knee Surgery, Sports Traumatology, Arthroscopy. 2019;27(6):1992-2002. https://pubmed.ncbi.nlm.nih.gov/30159738/
[2] Webner D, Huang Y, Hummer CD III. Intraarticular hyaluronic acid preparations for knee osteoarthritis: are some better than others? Cartilage. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8808930/
[3] Anika Therapeutics, Inc. MONOVISC® Instructions for Use. https://anika.com/products/oapm/monovisc/
[4] Centers for Medicare & Medicaid Services. Hyaluronic Acid Injections for Knee Osteoarthritis. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39260&ver=5
[5] Anika Therapeutics. FDA Approves MONOVISC®, A New Single Injection Treatment for Pain Due to Osteoarthritis of the Knee. Anika Therapeutics Investor Relations. https://ir.anika.com/FDA-Approves-MONOVISC-R-,-A-New-Single-Injection-Treatment-for-Treatment-of-Pain-Due-to-Osteoarthritis-of-the-Knee
All content on this website is intended for informational purposes and does not constitute medical advice.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.
